- Home
- GALT vs PCLA Comparison
GALT vs PCLA Comparison
Compare GALT & PCLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- PCLA
- Stock Information
- Founded
- GALT 2000
- PCLA 2008
- Country
- GALT United States
- PCLA Japan
- Employees
- GALT N/A
- PCLA N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- PCLA Building Products
- Sector
- GALT Health Care
- PCLA Consumer Discretionary
- Exchange
- GALT Nasdaq
- PCLA Nasdaq
- Market Cap
- GALT 83.5M
- PCLA 71.3M
- IPO Year
- GALT N/A
- PCLA 2025
- Fundamental
- Price
- GALT $2.80
- PCLA $0.81
- Analyst Decision
- GALT Buy
- PCLA
- Analyst Count
- GALT 2
- PCLA 0
- Target Price
- GALT $6.00
- PCLA N/A
- AVG Volume (30 Days)
- GALT 1.5M
- PCLA 3.2M
- Earning Date
- GALT 08-12-2025
- PCLA 01-01-0001
- Dividend Yield
- GALT N/A
- PCLA N/A
- EPS Growth
- GALT N/A
- PCLA N/A
- EPS
- GALT N/A
- PCLA N/A
- Revenue
- GALT N/A
- PCLA $5,475,228.00
- Revenue This Year
- GALT N/A
- PCLA N/A
- Revenue Next Year
- GALT N/A
- PCLA N/A
- P/E Ratio
- GALT N/A
- PCLA N/A
- Revenue Growth
- GALT N/A
- PCLA 40.19
- 52 Week Low
- GALT $0.73
- PCLA $0.37
- 52 Week High
- GALT $3.90
- PCLA $9.80
- Technical
- Relative Strength Index (RSI)
- GALT 67.38
- PCLA N/A
- Support Level
- GALT $2.07
- PCLA N/A
- Resistance Level
- GALT $2.36
- PCLA N/A
- Average True Range (ATR)
- GALT 0.24
- PCLA 0.00
- MACD
- GALT 0.03
- PCLA 0.00
- Stochastic Oscillator
- GALT 81.11
- PCLA 0.00
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About PCLA PicoCELA Inc. American Depositary Shares
PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.